| The number of dead | The number of living | Survival rate median (95% CI), months | p log-rank test | HR (95% CI) | p value |
Stage |
|
|
|
|
|
|
I-II | 44 (41.5%) | 62 (58.5%) | 84.0 (45.6 - 122.5) | <0.0001 | 1.00 | <0.0001 |
III-IV | 44 (65.7%) | 23 (34.3%) | 18.4 (9.6 - 27.1) |
| 1.60 (1.30 - 1.95) |
|
Histology |
|
|
|
|
|
|
Squamous cell carcinoma | 53 (58.2%) | 38 (41.8%) | 39.6 (24.5 - 54.7) | 0.079 | 1.00 | 0.86 |
Adenocarcinoma | 35 (42.7%) | 47 (57.3%) | 67.1 (51.4 - 88.8) |
| 0.98 (0.62 - 1.54) |
|
gender |
|
|
|
|
|
|
female | 9 (22.5%) | 31 (77.5%) | 108.5 (87.2 - 129.8) | <0.0001 | 1.00 | 0.007 |
male | 79 (59.4%) | 54 (40.6%) | 39.7 (29.7 - 49.8) |
| 2.77 (1.32 - 5.82) |
|
GSTТ1 |
|
|
|
|
|
|
GSTТ1 (del) | 16 (47.1%) | 18 (52.9%) | 49.8 (0.2 - 105.1) | 0. 60 | 1.00 | 0.18 |
GSTТ1 (+) | 72 (51.8%) | 67 (48.2%) | 50.8 (31.2 - 70.8) |
| 0.68 (0.38 - 1.19) |
|
GSTМ1 |
|
|
|
|
|
|
GSTМ1 (del) | 47 (50.0%) | 47 (50.0%) | 51.6 (30.5 - 72.8) | 0.72 | 1.00 | 0.09 |
GSTМ1 (+) | 41 (51.9%) | 38 (48.1%) | 40.9 (14.9 - 66.9) |
| 0.68 (0.43 - 1.06) |
|
GSTP1 |
|
|
|
|
|
|
AA | 43 (48. 9%) | 45 (51.1%) | 52.1 (25.5 - 78.7) | 0.43 | 1.00 | 0.97 |
GA | 38 (55.9%) | 30 (44.1%) | 40.9 (20.4 - 61.4) |
| 1.10 (0.48 - 2.48) |
|
GG | 7 (41.2) | 10 (58.8) | 96.4 (62.2 - 130.6) |
| 1.01 (0.48 - 2.50) |
|